MedTrace Logo

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

NCT06089278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-07-14

No results posted yet for this study

Summary

To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.

Conditions

  • Sinusitis

Interventions

DRUG

300mg of TQH2722 injection

TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

DRUG

600mg of TQH2722 injection

TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

DRUG

TQH2722 injection matching placebo

Placebo without active substance.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-28
Primary Completion
2025-03-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089278 on ClinicalTrials.gov